Pathophysiology of Renal Disease

Preconditioning and Adenosine Protect Human Proximal Tubule Cells in an In Vitro Model of Ischemic Injury

H. Thomas Lee and Charles W. Emala
JASN November 2002, 13 (11) 2753-2761; DOI: https://doi.org/10.1097/01.ASN.0000032421.79225.6E

Abstract

ABSTRACT. Renal ischemic reperfusion injury results in unacceptably high mortality and morbidity during the perioperative period. It has been recently demonstrated that ischemic preconditioning or adenosine receptor modulations attenuate renal ischemic reperfusion injury in vivo. An in vitro model of ischemic renal injury was used in cultured human proximal tubule (HK-2) cells to further elucidate the protective signaling cascades against renal ischemic reperfusion injury. ATP depletion preconditioning (1 h of antimycin A and 2-deoxyglucose treatment followed by 1 h of recovery), adenosine, an A1 adenosine receptor selective agonist, or an A2a adenosine receptor selective agonist significantly attenuated subsequent severe ATP depletion injury of HK-2 cells. In contrast, an adenosine receptor antagonist failed to prevent protection induced by ATP depletion preconditioning. Cytoprotection by ATP depletion preconditioning or A1 adenosine receptor activation was prevented by inhibitors of extracellular signal-regulated mitogen-activated kinases, protein kinase C, and tyrosine kinases. The A1 and A2a adenosine receptor-mediated cytoprotection were also dependent on Gi/o proteins and PKA activation, respectively. It is concluded that ATP depletion preconditioning and A1 and A2a adenosine receptor activation protect HK-2 cells against severe ATP depletion injury via distinct signaling pathways.

The A1 and A2a adenosine receptors serve to protect against ischemic reperfusion injury in many organ systems, including the heart, brain, liver, and kidney (1–9). We have recently demonstrated that pre- or post-ischemic activation of renal A1 and A2a adenosine receptors, respectively, protected renal function against ischemic reperfusion injury in vivo (3–5). The mechanism of pre-ischemic A1 adenosine receptor-mediated renal protection in vivo involved protein kinase C (PKC) and pertussis toxin–sensitive G-proteins (Gi/o), whereas post-ischemic A2a adenosine receptor–mediated protection was through protein kinase A (PKA) activation via cAMP.

Ischemic preconditioning, defined as multiple cycles of brief ischemia and reperfusion before a prolonged ischemic insult, was first described in cardiac tissue and subsequently demonstrated in skeletal muscle (10), brain (11), and liver (6). In these organs, ischemic preconditioning is mediated by activation of adenosine receptors. Ischemic preconditioning in cardiac and cerebral tissues also involves extracellular signal-regulated mitogen-activated kinases (12). We have recently demonstrated renal protective effects of ischemic preconditioning in vivo via mechanisms involving Gi/o and PKC (3). However, in contrast to cardiac, cerebral, and hepatic models, renal ischemic preconditioning in vivo was not blocked by adenosine receptor antagonism.

In vivo models pose limitations in the further elucidation of the signaling cascades mediating cytoprotection by adenosine receptor or ischemic preconditioning. Therefore, we used a pure population of human renal proximal tubular (HK-2) cells to study the signaling cascades directly. HK-2 cells are immortalized adult human proximal tubular cells transfected with E6/E7 genes of a human papilloma virus (HPV 16 [13,14]). Transfection with HPV16 has been shown to immortalize epithelial cells of diverse origin without significantly altering their phenotype or function. HK-2 cells have been shown to retain the phenotypic expression and functional characteristics of human proximal tubules (13,14). Many studies have utilized HK-2 cells to study in vitro renal physiology and pathology (15–17).

There are few studies of in vitro renal cell protection with adenosine receptor modulations or with ischemic preconditioning. Massive depletion of intracellular ATP and glucose and a large increase in intracellular calcium are the hallmark intracellular changes in cells undergoing lethal ischemic insult (18,19). We have used an in vitro model of anoxia/ischemia, causing severe ATP depletion by using the combination of a mitochondrial respiration inhibitor (antimycin A), a non-metabolizable glucose analog (2-deoxyglucose), and a calcium ionophore (A23187) in human renal cells to mimic the ischemic phase of renal ischemic reperfusion injury (15). Our goal was to extend our in vivo findings into an in vitro model to further elucidate the signal transduction pathways of renal protection induced by ischemic preconditioning or adenosine receptor modulations. We hypothesized that, as we observed in vivo, A1 adenosine receptor activation or ATP depletion preconditioning would protect against severe ATP depletion injury in human renal proximal tubule cells.

Materials and Methods

HK-2 Cell Culture

HK-2 cells (immortalized human proximal tubular cell line; American Type Culture Collection, Manassas, VA) were grown and passaged in 75-cm2 cell culture flasks containing culture medium (keratinocyte serum-free medium plus 5 ng/ml epidermal growth factor and 40 mg/ml bovine pituitary extract) and antibiotics (100 U/ml penicillin G, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B) at 37°C in a 100% humidified atmosphere of 5% CO2–95% air.

Induction of Severe ATP Depletion Injury with ATP/Glucose Depletion and Calcium Inophore in HK-2 Cells

When HK-2 cells were confluent, the culture medium was replaced with Hank’s balanced salt solution (HBSS; containing 1.3 mM Ca++ and 0.8 mM Mg++). In preliminary experiments, we determined that simply depleting ATP and glucose (with 10 μM antimycin A, a complex III inhibitor of mitochondrial electron transport, and 10 mM 2-deoxyglucose, a non-metabolizable isomer of l-glucose, respectively) failed to produce significant human proximal tubular (HK-2) cell death within 2 h. Therefore, rapid HK-2 cell injury was induced using a method of ATP and glucose-depletion plus 1 to 5 μM calcium ionophore (A23187) for 1 to 3 h. This model of ATP depletion injury in HK-2 cells has been widely used and extensively characterized (13,20–23).

A confluent monolayer of HK-2 cells grown in 6- or 24-well plates was incubated with antimycin A, 2-deoxyglucose, and 1, 2, or 5 μM calcium ionophore for 1 to 3 h (severe ATP depletion injury). The 2-h time point and 2 μM calcium ionophore were chosen for the subsequent studies, as this time and dose of calcium ionophore reproducibly induced moderate cellular injury. Some wells were pretreated (e.g., adenosine or adenosine receptor agonists) before severe ATP depletion injury. Other cells were preconditioned with 1 h of moderate ATP depletion (approximately 40% of baseline) using 10 μM antimycin A and 10 mM 2-deoxyglucose and then allowed to recover for 1 h before severe ATP depletion injury. In further experiments, inhibitors of ERK1/2, PKC, tyrosine kinase, or Gi/o were given before receptor agonists or preconditioning and then severe ATP depletion injury was induced. The drugs used and duration of pretreatments for selective inhibitors of signal transduction intermediates and adenosine receptor agonists and antagonist are listed in Table 1.

View this table:

Table 1. Selective adenosine receptor agonists and antagonist and selective inhibitors of signaling intermediates utilized

Measurement of Cell Viability and Cell Death

After severe ATP depletion injury, cell viability assays were performed using trypan blue dye exclusion. After the treatment protocols (e.g., injury ± adenosine receptor agonists), cells were trypsinized and stained with 0.4% trypan blue dye for 5 min. Preliminary studies demonstrated that trypsinization alone had no measurable effect on cell viability (data not shown). The proportion of nonviable cells (unable to exclude trypan blue) was counted using a hemocytometer and expressed as a percent of the total number of cells.

Lactate dehydrogenase (LDH) released into the media was also measured as a marker of cellular injury using a commercially available colorimetric method (Sigma, St. Louis, MO). In some experiments, LDH released into the media was expressed as the percent of total cellular LDH measured after lysing the cells with 1% Triton-X. Otherwise, LDH release after the various treatment protocols (e.g., ATP and glucose depletion plus calcium ionophore mediated severe ATP depletion injury ± adenosine receptor agonists) was expressed as the percent of LDH release by severe ATP depletion injury alone. n = 1 denotes average values of LDH released or trypan blue uptake obtained from duplicate wells in a single plate.

Measurement of Intracellular ATP Content

Intracellular ATP content in HK-2 cells (per well in a 24-well plate) after various combinations of metabolic inhibitors were determined using a commercially available quantitative enzymatic method at 340 nm (Sigma).

Immunoblotting of Activated Form of ERK

We measured ERK1/2 activation in HK-2 cells following ATP/glucose depletion and calcium ionophore injury by immunoblotting with antibodies to the phosphorylated forms of ERK1/2 (pERK1/2; Santa-Cruz Biotechnologies, Santa Cruz, CA) as described previously (2).

Protein Determination

Protein content was determined with the Pierce Chemical (Rockford, IL) bicinchoninic acid protein assay reagent with bovine serum albumin (BSA) as a standard.

Statistical and Data Analyses

The data were analyzed with t test when comparing means between two groups or with one-way ANOVA plus Dunnett post hoc multiple comparison test to compare mean values across multiple treatment groups.

Materials

Adenosine was dissolved in saline. All other drugs were dissolved first in DMSO and then were diluted in water such that the final concentration of DMSO in each experimental condition was <0.01%. Solutions were made daily. Unless specified, all chemicals were obtained from the Sigma Chemical Company.

Results

Depletion of Intracellular ATP by Antimycin A, 2-Deoxyglucose, and Calcium Ionophore

We used an in vitro model of ischemic injury using a combination of ATP and glucose depletion (antimycin A and 2-deoxyglucose) superimposed with calcium overload (calcium ionophore [A23187]) in HK-2 cells (severe ATP depletion injury) (15,20). This method of cellular injury produced significant ATP depletion, as intracellular ATP levels incrementally decreased with 2 h of 10 μM antimycin A (6.2 ± 0.2 μmol/dl per well, n = 6, P < 0.01 versus controls; 8.6 ± 0.9 μmol/dl per well, n = 6), 10 μM antimycin A + 10 mM 2-deoxyglucose (3.5 ± 0.6 μmol/dl per well, n = 6, P < 0.01 versus controls, P < 0.01 versus antimycin A only group), and 10 μM antimycin A + 10 μM 2-deoxyglucose + 2 μM calcium ionophore (1.8 ± 0.6 μmol/dl per well, n = 6, P < 0.01 versus controls, P < 0.01 versus antimycin A only group) treatments. ATP depletion preconditioning (8.1 ± 1.1 μmol/dl per well, n = 3, P < 0.05 versus severe ATP depletion injury) and pretreatment with 100 μM adenosine (7.0 ± 1.7 μmol/dl per well, n = 3, P < 0.05 versus severe ATP depletion injury), 10 μM R-PIA (6.6 ± 2.0 μmol/dl per well, n = 3, P < 0.05 versus severe ATP depletion injury), or 10 μM CGS-21680 (5.0 ± 1.8 μmol/dl per well, n = 3, P < 0.05 versus severe ATP depletion injury) prevented the severe decrease in intracellular ATP levels after injury.

Calcium Ionophore/ATP Depletion Injury Kills HK-2 Cells

As described by others (15), our pilot studies have demonstrated that simply depleting ATP and glucose without calcium ionophore treatment failed to kill HK-2 cells rapidly, as indicated by LDH release (<10% total cellular LDH released after 2 h). Therefore, we added a calcium ionophore (A23187) to facilitate HK-2 cell death, as a rapid and massive rise in intracellular calcium occurs in ischemic renal cell injury (18,19). Figure 1 shows that this method of calcium ionophore/ATP depletion injures HK-2 cells in a dose-dependent (Figure 1A; n = 3) and time-dependent (Figure 1B; n = 3) manner. HK-2 cell injury was quantified by measuring percent LDH released into the cell culture media and by the percent of trypan blue dye exclusion. The 2-h time point was chosen for subsequent studies because cell death plateaus at this time point, and 2 μM calcium ionophore was chosen because this dose induced moderate (approximately 60%) cellular injury.

Figure

Figure 1. (A) Severe ATP depletion (calcium ionophore plus ATP and glucose depletion) injures human proximal tubule (HK-2) cells in a calcium iopnophore dose-dependent manner (2-h incubation, n = 3). (B) The injury plateaus at 2 h of incubation (5 μM calcium ionophore data shown, n = 3). Cell injuries were quantified by measuring percent of total cellular LDH released into the culture media after specified incubation period and dose. * P < 0.05 versus vehicle-treated control group (n = 3). Error bars represent 1 SEM.

ATP Depletion Preconditioning and Adenosine Protect against Subsequent Calcium Ionophore/ATP Depletion Injury

Figure 2 shows that 1 h of moderate ATP depletion by pretreatments with 10 μM antimycin A and 10 mM 2-deoxyglucose followed by 1 h of recovery in normal cell culture medium (ATP depletion preconditioning) significantly protected against more severe ATP depletion injury induced by a combination of mitochondrial oxidative and glycolytic inhibitors (10 μM antimycin A and 10 mM 2-deoxyglucose, respectively) plus 2 μM calcium ionophore. After ATP depletion preconditioning, significantly less LDH (53.0 ± 3.1% of severe ATP depletion injury alone group, n = 6, P < 0.05, Figure 2A) was released into the cell culture media and more cells excluded trypan blue dye (9.7 ± 2.3% trypan blue–positive cells versus 33.4 ± 5.5% for severe ATP depletion injury group, n = 6, P < 0.05, Figure 2B). One hour of ATP depletion preconditioning itself resulted in 10.7 ± 1.4% of the cells taking up trypan blue dye (n = 6, P < 0.05 versus severe ATP depletion injury alone group).

Figure

Figure 2. ATP depletion preconditioning (AD PC, n = 6), 100 μM adenosine (ADO, n = 6), 10 μM A1 adenosine receptor selective agonist (PIA, n = 6), and 10 μM A2a adenosine receptor selective agonist (CGS, n = 6) pretreatment protect against severe ATP depletion (calcium ionophore/ATP depletion) injury in HK-2 cells (CAD, n = 6). 10 μM A3 adenosine receptor selective agonist (IB, n = 6) had no effect. Combination of ATP depletion preconditioning and adenosine (AD PC+ADO+CAD, n = 3) had no additive protection when compared with either ATP depletion preconditioning or adenosine pretreatment. Cell injuries were quantified by measuring LDH released into the culture media (A) or by the percent of trypan blue dye exclusion (B) from cells that underwent ATP depletion preconditioning (1 h of ATP depletion with antimycin A and 2-deoxyglucose before 1 h of recovery) or pretreated with adenosine, PIA, CGS, IB, or vehicle for 30 min, and subsequently injured with 10 μM antimycin A, 10 mM 2-deoxyglucose, and 2 μM calcium ionophore (CAD, n = 6) for 2 h. * P < 0.05 versus severe ATP depletion injury group (CAD). Error bars represent 1 SEM.

Figure 2 also shows that adenosine pretreatment for 30 min significantly protects against severe ATP depletion injury induced cell death. With 100 μM adenosine pretreatment, significantly less LDH (68.0 ± 2.5% of severe ATP depletion injury alone group, n = 6, P < 0.05, Figure 2A) was released into the cell culture media, and more cells excluded trypan blue dye (19.2 ± 2.6% trypan blue–positive cells, n = 6, P < 0.05, Figure 2B). In addition, we show that the combination of ATP depletion preconditioning plus adenosine receptor activation failed to demonstrate improved protection beyond either maneuver alone (LDH = 62.2 ± 6.1% of severe ATP depletion injury alone group, n = 3, P < 0.05, Figure 2A). ATP depletion preconditioning is not mediated by adenosine receptors as 100 μM 8-PT (a nonselective adenosine receptor antagonist) failed to block the cytoprotection by ATP depletion preconditioning (LDH = 63.1 ± 9.2% of severe ATP depletion injury alone group, n = 3).

A1 and A2a Adenosine Receptors Are Involved in Adenosine-Mediated Protection against Calcium Ionophore/ATP Depletion Injury

In HK-2 cells, adenosine-mediated protection against severe ATP depletion injury involves the A1 and A2a adenosine receptors, as the A1 adenosine receptor agonist R-PIA (Figures 2 and 3A) and the A2a adenosine receptor agonist CGS-21680 (Figures 2 and 3B) pretreatment provided dose-dependent protection against severe ATP depletion injury. The LDH release in HK-2 cells pretreated with 10 μM R-PIA and 10 μM CGS-21680 were 64.5 ± 2.5% (n = 9) and 63.1 ± 3.8% (n = 6) of the severe ATP depletion injury alone group, respectively. The trypan blue uptake of cells treated with 10 μM R-PIA (17.0 ± 4.5% of total cells, n = 6) and 10 μM CGS-21680 (12.5 ± 2.3% of total cells, n = 6) were also significantly reduced when compared with the severe ATP depletion injury alone group (33.4 ± 5.5% of total cells, n = 6). The A3 adenosine receptor agonist IB-MECA (10 μM) failed to protect against severe ATP depletion injury (LDH release of 96.3 ± 2.9% of severe ATP depletion injury alone group, n = 6, Figure 3A; trypan blue uptake of 32.5 ± 5.1% of total cells, n = 6, Figure 2B).

Figure

Figure 3. The A1 adenosine receptor agonist (PIA; panel A; n = 6) and the A2a adenosine receptor agonist (CGS; panel B; n = 6) attenuate severe ATP depletion-mediated HK-2 cell injury (CAD; n = 6) in dose-dependent manners. Cell injuries were quantified by measuring LDH released into the culture media from cells treated with 1 nM to 10 μM PIA or 0.01 to 10 μM CGS or vehicle for 30 min before the addition of 10 μM antimycin A, 10 mM 2-deoxyglucose, 2 μM and calcium ionophore (CAD, n = 6) for 2 h. * P < 0.05 versus severe ATP depletion injury group (CAD). Error bars represent 1 SEM.

Signaling Pathways of ATP Depletion Preconditioning and A1 Adenosine Receptor-Mediated Protection

We used specific inhibitors of Gi/o proteins (pertussis toxin), tyrosine kinases (genistein), MEK-1 (PD98059 to inhibit ERK1/2 activation), and PKC (GF-109203X [Bisindolylmaleimide I]) to determine the involvement of these signaling intermediates in ATP depletion preconditioning and in A1- and A2a adenosine receptor-mediated protection against subsequent severe ATP depletion injury. We first demonstrated that these inhibitors alone or with severe ATP depletion injury had no effect on LDH released or trypan blue uptake in HK-2 cells (data not shown). Pretreatment with pertussis toxin (100 ng/ml for 14 h, n = 6), PD98059 (50 μM for 30 min, n = 3), genistein (20 μm for 30 min, n = 3), or GF-109203X (100 nM for 30 min, n = 6) blocked A1 adenosine receptor-mediated protection from severe ATP depletion injury conferred by 10 μM PIA (LDH = 97.9 ± 3.1%, 97.3 ± 5.7%, 105 ± 6.6%, and 98.3 ± 4.9% of severe ATP depletion injury alone group, respectively; Figure 4A). In addition, PD98059 (n = 3), genistein (n = 3), or GF-109203X (n = 6) blocked the protection conferred by ATP depletion preconditioning to subsequent severe ATP depletion injury (LDH = 97.3 ± 5.7%, 99.2 ± 14.0%, and 98.3 ± 4.9% of severe ATP depletion injury alone group, respectively; Figure 4A). In contrast, the nonselective adenosine receptor antagonist (100 μM 8-PT, LDH = 56.0 ± 4.7% of severe ATP depletion injury alone group, n = 6) or pertussis toxin (100 ng/ml, LDH = 65.3 ± 3.3% of severe ATP depletion injury alone group, n = 3) failed to block protection conferred by ATP depletion preconditioning. Additionally, pertussis toxin, genistein, PD98059 or GF-109203X failed to block the A2a adenosine receptor-mediated protection against severe ATP depletion injury conferred by 10 μM CGS-21680 (data not shown). Taken together, these results suggest that (1) A1 adenosine-mediated protection involves Gi/o proteins, MEK-1 → ERK, tyrosine kinases, and PKC; (2) ATP depletion preconditioning involves MEK-1 → ERK, tyrosine kinases, and PKC but not adenosine receptors or Gi/o proteins; and (3) A2a adenosine receptor-mediated protection does not involve Gi/o proteins, MEK-1, tyrosine kinases, or PKC.

Figure

Figure 4. The A1 adenosine receptor-mediated protection against severe ATP depletion-mediated HK-2 cell injury is mediated by pertussis toxin-sensitive G-proteins, ERK, protein kinase C, and tyrosine kinases (panel A, n = 6), whereas the A2a adenosine receptor-mediated protection involves PKA activation by cAMP (panel B, n = 6). ATP depletion preconditioning (AD PC) is mediated by ERK, protein kinase C, and tyrosine kinases (panel A, n = 6). Cell injuries were quantified by measuring LDH released into the culture media from cells pretreated with an inhibitor (of Gi/o ERK, PKC, tyrosine kinase, or PKA) 30 min before PIA or CGS treatment, which were applied 30 min before calcium ionophore/ATP depletion-mediated HK-2 cell injury (CAD, n = 6). PIA and CGS, 10 μM A1 and A2a adenosine receptor selective agonist, respectively (30-min pretreatment); PTX, pertussis toxin (100 ng/ml, 14-h pretreatment); GF, protein kinase C antagonist (GF-109203X [Bisindolylmaleimide I], 100 nM, 30-min pretreatment); Genist, tyrosine kinase antagonist (genistein, 20 μM, 30-min pretreatment); Sp, protein kinase A agonist (Sp-cAMPS, 100 μM, 30-min pretreatment); Rp, protein kinase A antagonist (Rp-cAMPS, 100 μM, 30-min pretreatment). * P < 0.05 versus severe ATP depletion injury group (CAD); # P < 0.05 versus PIA+CAD group; $ P < 0.05 versus AD PC+CAD group; % P < 0.05 versus CGS+CAD group. Error bars represent 1 SEM.

A2a Adenosine Receptors Protect via cAMP → Protein Kinase A (PKA)

The A2a adenosine receptor-mediated cytoprotection against severe ATP depletion injury involves PKA because the PKA antagonist Rp-cAMPS inhibited the A2a adenosine receptor agonist-induced protection against severe ATP depletion injury (100 μM, 30-min pretreatment, LDH = 87.2 ± 3.9% of severe ATP depletion injury alone group, n = 6, P < 0.05 versus 10 μM CGS-21680 treated group, Figure 4B). Rp-cAMPS itself had no effect on severe ATP depletion injury (data not shown). Moreover, the PKA agonist Sp-cAMPS mimicked the protection provided by the A2a adenosine receptor agonist (100 μM, 30-min pretreatment, LDH = 75.0 ± 3.9% of severe ATP depletion injury alone group, n = 3).

Role of ERK1/2 in Calcium Ionophore/ATP Depletion Injury

We have recently demonstrated that activation of A1 adenosine receptors in HK-2 cells results in phosphorylation (activation) of ERK1/2 via Gi and tyrosine kinase (24). We provide further evidence that ERK1/2 activation is required for protection against severe ATP depletion injury with immunoblotting approaches (Figure 5). Under basal conditions, HK-2 cells express large amounts of p-ERK1/2, and the 42-kD p-ERK2 is the predominant subtype of activated ERK. This p-ERK1/2 expression is significantly abolished with severe ATP depletion injury. One hour of ATP depletion preconditioning (1 h of antimycin A and 2-deoxyglucose followed by 1 h of recovery in normal cell culture media) prevented the loss of activated ERK1/2 after severe ATP depletion injury. Moreover, A1 adenosine receptor activation, but not A2a adenosine receptor activation, significantly preserved ERK1/2 activity after severe ATP depletion injury (Figure 5). Therefore, improved preservation of ERK1/2 activity correlates with improved cellular survival when HK-2 cells are subjected to severe ATP depletion injury.

Figure

Figure 5. (Top) Cytoprotective effects of ERK1/2 activation measured by phospho-specific antibody. Two hours of severe ATP depletion-mediated HK-2 cell injury profoundly attenuated the ERK1/2 phosphorylation (CAD, n = 6). ATP depletion preconditioning (AD PC, n = 6) and A1 adenosine receptor agonist (PIA, 10 μM, 30-min pretreatment, n = 6) rescued ERK1/2 phosphorylation. The A2a adenosine receptor agonist (CGS, 10 μM, 30-min pretreatment) had no effect on ERK1/2 activity. Genistein (Genist), a tyrosine kinase inhibitor (20 μM, 30-min pretreatment) blocked ATP depletion preconditioning-mediated ERK rescue (AD PC+Genist+CAD, n = 6). * P < 0.05 versus control; # P < 0.05 versus CAD group. Error bars represent 1 SEM. (Bottom) Representative immunoblot of HK-2 cell lysates with phosphospecific ERK1/2 (n = 2 shown for control, CAD, AD PC+CAD, PIA+CAD, CGS+CAD, and AD PC+Genist+CAD).

Discussion

The major new findings of the present study are that either ATP depletion preconditioning or adenosine receptor activation in vitro protects against cell death induced by subsequent calcium ionophore/ATP depletion-induced injury in human renal proximal tubule (HK-2) cells. Protection afforded by ATP depletion preconditioning involves extracellular signal-regulated kinases 1 and 2 (ERK1/2), protein kinase C (PKC), and tyrosine kinase, but it is independent of adenosine receptor or Gi/o protein activation. Moreover, both A1 and A2a adenosine receptor agonists protected HK-2 cells against the direct cytotoxic effects of severe ATP depletion injury (non–receptor-mediated cytotoxicity) via distinct receptor-mediated cellular mechanisms. A2a adenosine receptor-mediated protection involves the cAMP → protein kinase A (PKA) pathway, whereas A1 adenosine receptor-mediated protection involves Gi/o, PKC, tyrosine kinase, and ERK1/2: signaling intermediates frequently implicated in protection from ischemic reperfusion injury in the myocardium (25) and in the kidney (3–5,26). Cytoprotection by ATP depletion preconditioning and AR activation is associated with significantly improved cellular ATP levels. These in vitro findings complement our previous in vivo studies in which differential adenosine receptor modulations protected against global renal ischemic reperfusion injury (3–5). In addition, as we observed in vivo, preconditioning-mediated protection was independent of adenosine receptor activation in vitro.

Profound intracellular ATP depletion and a fall in tissue oxygen content with a concomitant rise in intracellular calcium are the hallmark features of renal ischemic-reperfusion injury (18,19). Intracellular calcium levels rise after anoxia and ATP depletion, and this rise in calcium contributes further to the necrotic cellular death. In this study, we produced ATP/glucose depletion-calcium ionophore–mediated HK-2 cell death as an in vitro model of ischemic or ATP depletion injury. This injury was achieved by a combination of metabolic inhibitors (antimycin A and 2-deoxyglucose) and a calcium ionophore (A23187). Addition of a calcium ionophore has been employed frequently to induce lethal ATP depletion injury in HK-2 cells (13,20–23), as the metabolic inhibitors alone fail to produce rapid cellular death and measurable LDH release. Iwata et al. (15) have demonstrated that the combination of ATP and glucose depletion with antimycin A and 2-deoxyglucose, respectively, produces approximately 90% ATP depletion but fails to rapidly kill HK-2 cells. Epithelial cells, such as HK-2 cells, are glycolytic and can utilize amino acids via gluconeogenesis to produce glucose and, therefore, are not susceptible to rapid hypoxic/anoxic cell death (personal communication with Dr. Richard Zager, University of Washington, July 1999). Moreover, true anoxia by removing O2 from the cell culture environment is often impractical to achieve. We demonstrate that cytoprotection by ATP depletion preconditioning and adenosine receptor activation is associated with significantly higher cellular ATP levels.

Currently, there are four subtypes of identified adenosine receptors (A1, A2a, A2b, and A3 adenosine receptors) that mediate extracellular action of adenosine in the kidney (27). Adenosine also acts intracellularly to increase the level of S-adenosylhomocysteine (SAH) by inhibiting SAH hydrolase (28). We have recently verified the presence of all four subtypes of adenosine receptors and demonstrated several key signaling intermediates in HK-2 cells (24). Adenosine has cytoprotective effects in several cell types including renal cells (2–5). Adenosine receptor activation, specifically the A1 and A2a subtypes, attenuates several factors responsible for generating ischemic-reperfusion injury (29). A1 adenosine receptor activation attenuates ischemic-reperfusion injury when given before the ischemic insult in cerebral (9,30), cardiac (29), and renal (3) cells. Conversely, post-ischemic A2a adenosine receptor activation also protects against tissue injury by attenuating the reperfusion phase of injury process in pulmonary (31), cardiac (7), and renal (5,32) cells.

Activation of ERK1/2 by ATP depletion preconditioning or the A1 adenosine receptor agonist R-PIA potently protected against subsequent severe ATP depletion injury in our study. This is consistent with the finding that preservation of ERK1/2 activity correlates with improved cellular survival after ATP depletion injury (12). In mouse renal proximal tubules, cell survival after ischemic-reperfusion injury is dependent on ERK1/2 activation (26). In murine inner collecting duct cells, ERK activation correlates with markedly reduced cell loss after ATP depletion (33). Additionally, an important role of ERK1/2 activation has been implicated in cardiac and cerebral ischemic preconditioning (12). In a recent study of neuronal ischemic preconditioning, oxygen-glucose deprivation preconditioning (analogous to our ATP depletion preconditioning) was neuroprotective via mechanisms involving p21ras and ERK1/2 (34). Similar to our study, their preconditioning stimulus produced robust ERK1/2 activation, and this activation was required for protection against subsequent and more severe ischemic/ATP depletion injury. The mechanism by which ERK1/2 activation leads to cytoprotection in both A1 adenosine receptor activation and ATP depletion preconditioning is not known but may involve ERK1/2’s pro-survival/anti-apoptotic pathways and/or new gene expression and new protein synthesis. ERK activation may also increase the cellular repair capacity of renal epithelial cells (26).

We also demonstrate in this study that A2a adenosine receptor activation protected against severe ATP depletion injury in HK-2 cells via cyclic AMP-dependent signaling pathways that are distinct from A1 adenosine receptor activation-mediated cytoprotection. We and others have previously demonstrated that A2a adenosine receptor activation protects against renal ischemic-reperfusion injury in vivo (35) and that the A2a adenosine receptor is the receptor subtype frequently implicated in the attenuation of reperfusion injury (36). Stimulation of A2a adenosine receptors, including those present in renal tubule cells and vasculature, classically result in increased cellular cAMP to activate PKA (37). It has been suggested that increased intracellular cAMP protects against renal reoxygenation/oxidant injury in both in vivo (38) and in vitro (39,40) models. The mechanism of cAMP’s protection against severe ATP depletion injury is not clear. It does not involve ERK1/2 as we have previously demonstrated that A2a adenosine receptors failed to activate ERK1/2 (24), and the ERK inhibitor failed to prevent A2a adenosine receptor-mediated protection against severe ATP depletion injury in this study. The adenosine A2a agonist (10 μM CGS-21680) failed to preserve p-ERK1/2 expression after severe ATP depletion-induced injury indicating that A2a receptor activation mediates protection from severe ATP depletion injury by a different mechanism than the protection mediated by adenosine A1 receptor activation (which is p-ERK1/2-dependent).

The present in vitro study illustrates remarkable similarities to our previous in vivo findings (4); (1) both A1 and A2a adenosine receptor activations produce cytoprotection against severe ATP depletion-induced injury; (2) ATP depletion preconditioning, an in vitro model of renal ischemic preconditioning, is mediated via Gi/o, tyrosine kinase, and ERK1/2; and (3) protection afforded by preconditioning is independent of adenosine receptor activation. Moreover, we showed that the cytoprotection observed with ATP depletion preconditioning and adenosine receptor activation is not additive; that is, combination of ATP depletion preconditioning and adenosine receptor failed to demonstrate improved protection from either maneuver alone. Consistent with our in vivo and current in vitro studies, previous studies in the heart illustrate that transient glucose deprivation confers a preconditioning-like protection against subsequent ischemic reperfusion injury (41) via mechanisms involving PKC.

In summary, this is the first report of in vitro protective effects of adenosine receptors and ATP depletion preconditioning against subsequent severe ATP depletion-induced injury in human proximal tubule cells. We have systematically deciphered the signaling pathways of A1 and A2a adenosine receptor-mediated renal cytoprotection as well as protection by prior ATP depletion preconditioning. As we observed with in vivo ischemic preconditioning, in vitro ATP depletion preconditioning confers cytoprotection via adenosine receptor-independent pathways

Acknowledgments

This work was funded by intramural grant support from the Department of Anesthesiology, Columbia University College of Physicians and Surgeons, and by National Institute of Health grant RO-1 DK-58547.

References

  1. ↵
    Lee HT: Mechanisms of ischemic preconditioning and clinical implications for multiorgan ischemic-reperfusion injury. J Cardiothorac Vasc Anesth 13: 78–91, 1999
    OpenUrlCrossRefPubMed
  2. ↵
    Lee HT, Emala C: Adenosine attenuates oxidant injury in human kidney proximal tubular cells via A1 and A2a adenosine receptor activation. Am J Physiol Renal Physiol 282: F844–F852, 2002
    OpenUrlCrossRefPubMed
  3. ↵
    Lee HT, Emala, CW: Protective effects of renal ischemic preconditioning and adenosine pretreatment: Role of A(1) and A(3) receptors. Am J Physiol Renal Physiol 278: F380–F387, 2000
    OpenUrlPubMed
  4. ↵
    Lee HT, Emala C: Protein kinase C and Gi/o proteins are involved in adenosine- and ischemic preconditioning-mediated protection of renal ischemic-reperfusion injury. J Am Soc Nephrol 12: 233–240, 2001
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Lee HT, Emala CW: Systemic adenosine given after ischemia protects renal function via A2a adenosine receptor activation. Am J Kidney Dis 38: 610–618, 2001
    OpenUrlPubMed
  6. ↵
    Peralta C, Hotter G, Closa D, Prats N, Xaus C, Gelpi E, Roselló-Catafau J: The protective role of adenosine in inducing nitric oxide synthesis in rat liver ischemia preconditioning is mediated by activation of A2 receptors. Hepatology 29: 126–132, 1999
    OpenUrlCrossRefPubMed
  7. ↵
    Schlack W, Schafer M, Uebing A, Schafer S, Borchard U, Thamer V: Adenosine A2-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart. J Cardiovasc Pharmacol 22: 89–96, 1993
    OpenUrlCrossRefPubMed
  8. Thornton JD, Liu GS, Olsson RA, Downey JM: Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circ Res 85: 659–665, 1992
    OpenUrlCrossRef
  9. ↵
    Heurteaux C, Lauritzen I, Widmann C, Lazdunski M: Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K+ channels in cerebral ischemic preconditioning. Proc Natl Acad Sci USA 92: 4666–4670, 1995
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Lee HT, Schroeder CA, Shah P, Babu S, Thompson CI, Belloni FL: Preconditioning with ischemia or adenosine protects skeletal muscle from ischemic tissue reperfusion injury. J Surg Res 63: 29–34, 1996
    OpenUrlCrossRefPubMed
  11. ↵
    Tauskela JS, chakravarthy, BR, Murray CL, Wang Y, Comas T, Hogan M, Hakim A, Morley P: Evidence from cultured rat cortical neurons of differences in the mechanism of ischemic preconditioning of brain and heart. Brain Res 827: 143–151, 1999
    OpenUrlCrossRefPubMed
  12. ↵
    Fryer RM, Pratt PF, Hsu AK, Gross GJ: Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. J Pharmacol Exp Ther 296: 642–649, 2001
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B: HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney: Kidney Int 45: 48–57, 1994
    OpenUrlCrossRefPubMed
  14. ↵
    Racusen LC, Monteil C, Sgrignoli A, Lucskay M, Marouillat S, Rhim JG, Morin JP: Cell lines with extended in vitro growth potential from human renal proximal tubule: Characterization, response to inducers, and comparison with established cell lines. J Lab Clin Med 129: 318–329, 1997
    OpenUrlCrossRefPubMed
  15. ↵
    Iwata M, Herrington J, Zager RA: Protein synthesis inhibition induces cytoresistance in cultured human proximal tubular (HK-2) cells. Am J Physiol 268: F1154–F1163, 1995
  16. Lochhead KM, Zager RA: Fluorinated anesthetic exposure “activates” the renal cortical sphingomyelinase cascade. Kidney Int 54: 373–381, 1998
    OpenUrlCrossRefPubMed
  17. ↵
    Zager RA, Burkhart KM, Johnson AC, Sacks BM: Increased proximal tubular cholesterol content: implications for cell injury and “acquired cytoresistance”. Kidney Int 56: 1788–1797, 1999
    OpenUrlCrossRefPubMed
  18. ↵
    Kribben A, Wieder ED, Wetzels JF, Yu L, Gengaro PE, Burke TJ, Schrier RW: Evidence for role of cytosolic free calcium in hypoxia-induced proximal tubule injury. J Clin Invest 93: 1922–1929, 1994
  19. ↵
    Greene EL, Paller MS: Calcium and free radicals in hypoxia/reoxygenation injury of renal epithelial cells. Am J Physiol 266: F13–F20, 1994
  20. ↵
    Iwata M, Herrington J, Zager RA: Sphingosine: A mediator of acute renal tubular injury and subsequent cytoresistance. Proc Natl Acad Sci USA 92: 8970–8974, 1995
    OpenUrlAbstract/FREE Full Text
  21. Zager RA: Calcitriol directly sensitizes renal tubular cells to ATP-depletion- and iron-mediated attack. Am J Pathol 154: 1899–1909, 1999
    OpenUrlPubMed
  22. Zager RA, Burkhart KM, Conrad DS, Gmur DJ, Iwata M: Phospholipase A2-induced cytoprotection of proximal tubules: potential determinants and specificity for ATP depletion-mediated injury. J Am Soc Nephrol 7: 64–72, 1996
    OpenUrlAbstract
  23. ↵
    Garcia-Ocana, A, Galbraith SC, Van Why SK, Yang K, Golovyan L, Dann P, Zager RA, Stewart AF, Siegel NJ, Orloff, JJ: Expression and role of parathyroid hormone-related protein in human renal proximal tubule cells during recovery from ATP depletion. J Am Soc Nephrol 10: 238–244, 1999
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Lee HT, Emala CW: Characterization of adenosine receptors in human kidney proximal tubule (HK-2) cells. Exp Nephrol 2002, in press
  25. ↵
    Marber MS: Ischemic preconditioning in isolated cells. Circ Res 86: 926–931, 2000
    OpenUrlFREE Full Text
  26. ↵
    di Mari JF, Davis R, Safirstein RL: MAPK activation determines renal epithelial cell survival during oxidative injury: Am J Physiol 277: F195–F203, 1999
  27. ↵
    Fozard JR, Hannon, JP: Adenosine receptor ligands: Potential as therapeutic agents in asthma and COPD. Pulm Pharmacol Ther 12: 111–114, 1999
    OpenUrlCrossRefPubMed
  28. ↵
    Kloor D, Delabar U, Muhlbauer B, Luippold G, Osswald, H: Tissue levels of S-adenosylhomocysteine in the rat kidney: Effects of ischemia and homocysteine. Biochem Pharmacol 63: 809–815, 2002
    OpenUrlCrossRefPubMed
  29. ↵
    Vinten-Johansen, J, Zhao ZQ, Sato, H: Reduction in surgical ischemic-reperfusion injury with adenosine and nitric oxide therapy. Ann Thorac Surg 60: 852–857, 1995
    OpenUrlCrossRefPubMed
  30. ↵
    Phillis, JW: The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res 705: 79–84, 1995
    OpenUrlCrossRefPubMed
  31. ↵
    Adkins WK, Barnard JW, Moore TM, Allison RC, Prasad VR, Taylor, AE: Adenosine prevents PMA-induced lung injury via an A2 receptor mechanism. J Appl Physiol 74: 982–988, 1993
    OpenUrlPubMed
  32. ↵
    Okusa MD, Linden J, Macdonald T, Huang, L: Selective A2A adenosine receptor activation reduces ischemia- reperfusion injury in rat kidney. Am J Physiol 277: F404–F412, 1999
  33. ↵
    Liu ZX, Nickel CH, Cantley, LG: HGF promotes adhesion of ATP-depleted renal tubular epithelial cells in a MAPK-dependent manner. Am J Physiol Renal Physiol 281: F62–F70, 2001
    OpenUrlPubMed
  34. ↵
    Gonzalez-Zulueta, M, Feldman AB, Klesse LJ, Kalb RG, Dillman JF, Parada LF, Dawson TM, Dawson, VL: Requirement for nitric oxide activation of p21(ras)/extracellular regulated kinase in neuronal ischemic preconditioning. Proc Natl Acad Sci USA 97: 436–441, 2000
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Okusa MD, Linden J, Macdonald T, Huang, L: Selective A2A adenosine receptor activation reduces ischemia- reperfusion injury in rat kidney. Am J Physiol 277: F404–F412, 1999
  36. ↵
    Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 76: 5–13, 1994
    OpenUrlCrossRefPubMed
  37. ↵
    Ramkumar V, Pierson G, Stiles, GL: Adenosine receptors: Clinical implications and biochemical mechanisms. Prog Drug Res 32: 195–247, 1988
    OpenUrlPubMed
  38. ↵
    Carcillo JA, Herzer WA, Mi A, Thomas NJ, and Jackson E K: Treatment with the type IV phosphodiesterase inhibitor Ro 20–1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine. J Pharmacol Exp Ther 279: 1197–1204, 1996
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Kobayashi S and Millhorn D E: Stimulation of expression for the adenosine A2a receptor gene by hypoxia in PC12 cells. A potential role in cell protection. J Biol Chem 274: 20358–20365, 1999
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Yonehana T, Gemba, M: Ameliorative effect of adenosine on hypoxia-reoxygenation injury in LLC- PK1, a porcine kidney cell line [In Process Citation]. Jpn J Pharmacol 80: 163–167, 1999
    OpenUrlCrossRefPubMed
  41. ↵
    Awan MM, Makaula S, Forresti S, Sack MN, Opie, LH: Mechanisms whereby glucose deprivation triggers metabolic preconditioning in the isolated rat heart. Mol Cell Biochem 211: 111–121, 2000
    OpenUrlCrossRefPubMed
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Email Article
Citation Tools
Request Permissions
Preconditioning and Adenosine Protect Human Proximal Tubule Cells in an In Vitro Model of Ischemic Injury
H. Thomas Lee, Charles W. Emala
JASN Nov 2002, 13 (11) 2753-2761; DOI: 10.1097/01.ASN.0000032421.79225.6E
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

More in this TOC Section

Cited By...

Similar Articles

Related Articles

  • No related articles found.